Ragweed Pollen Allergy Treatment Market, by Drug Class (Antihistamines, Decongestants, Nasal Corticosteroids, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel), and by Region (North America, Latin America, Euro

Ragweed Pollen Allergy Treatment Market, by Drug Class (Antihistamines, Decongestants, Nasal Corticosteroids, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ragweed pollen is considered as one of the most common roots of seasonal allergies, especially in the U.S. The pollen present in ragweed plants is the main cause of this disease. These plants are found in 17 different types of species in North America. An autoimmune response is generated in ragweed allergy affected population. The immune cells of affected patients produces chemicals to combat the pollen considering it as a foreign substance. This reaction leads to various irritating symptoms, such as itchy eyes, running nose, and sneezing. However, these symptoms or allergy can be treated with allergy shots and medications.
Global Ragweed Pollen Allergy Treatment Market Dynamics
The increasing number clinical trials and development of novel treatment and therapies are the major factors boosting the growth of global ragweed pollen allergy treatment market. Moreover, the increasing pollution and changing environmental conditions are other factors propelling the market growth. For instance, according to the Asthma and Allergy Foundation of America (AAFA), in 2018, about 75% of people who are allergic to pollen are also allergic to ragweed. An individual who is allergic to one type of pollen, tends to develop allergies to other types of pollen as well.
Moreover, the rising number of approvals of ragweed pollen allergy treatment is expected to drive the overall market growth. For instance, Novartis AG received U.S. FDA approval for Xolair for the treatment of mild to severe persistent pollen allergy treatment in September 2018. Since the initial approval of Xolair, more than 330,000 Americans aged 12 years and older have been treated with pollen allergy and allergic asthma.
However, the lack of awareness related to allergy immunotherapy (AIT) and high cost of the treatment are some of the major factors restricting the growth of global ragweed pollen allergy treatment market.
Key features of the study:
This report provides in-depth analysis of the global ragweed pollen allergy treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global ragweed pollen allergy treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, and Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMerieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi, and Merck KGaA.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future drug launches, governmental initiatives, technological advancements, geographical expansion, and marketing tactics
The global ragweed pollen allergy treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the ragweed pollen allergy treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Ragweed Pollen Allergy Treatment Market, By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
Global Ragweed Pollen Allergy Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Global Ragweed Pollen Allergy Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Antihistamines
Decongestants
Nasal Corticosteroids
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Channel
Company Profiles
ALK-Abello A/S
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
ASIT Biotech SA
Anergis SA
Biomay AG
Astellas Pharma Inc.
Thermo Fisher Scientific Inc
Siemens Healthcare Private Limited
Omega Diagnostics Group PLC
Stallergenes Greer
bioMerieux SA
Lincoln Diagnostics, Inc
HOB Biotech Group Corp Ltd
HYCOR Biomedical, Inc
Alcon
Hitachi Chemical Diagnostics, Inc
Quest Diagnostics Incorporated
Circassia
Immunomic Therapeutics, Inc
Novartis AG
Japan Tobacco Inc
GlaxoSmithKline plc
REGiMMUNE Co, Ltd
Sanofi
Merck KGaA.
“*” marked represents similar segmentation in other categories in the respective section.